Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer

Kawaguchi, Kosuke; Suzuki, Eiji; Yamamoto, Mami; Yamaguchi, Ayane; Morita, Satoshi; Toi, Masakazu

doi:10.1016/j.ejca.2016.03.063

Cited by 1 publication

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the evaluation of PD‐L1 by liquid biopsy has emerged as a promising strategy potentially capable of better capturing the dynamic nature of this biomarker compared with its assessment on tumor tissue. Indeed, it has been stated that patients with BC frequently harbor PD‐L1‐positive circulating epithelial tumor cells , peripheral blood mononuclear cells , or circulating tumor RNA. Interestingly, it has also been reported that serum PD‐L1 is associated with tumor burden and outcome .…”

Section: Resultsmentioning

confidence: 99%

“…Indeed, it has been stated that patients with BC frequently harbor PD‐L1‐positive circulating epithelial tumor cells , peripheral blood mononuclear cells , or circulating tumor RNA. Interestingly, it has also been reported that serum PD‐L1 is associated with tumor burden and outcome . These preliminary data suggest that liquid biopsy may represent a noninvasive and feasible strategy for dynamic assessment and serial monitoring of PD‐L1 of patients with BC, thus potentially providing a real‐time picture of PD‐L1 status.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

2019

View full text Add to dashboard Cite

In the light of recent advances in the immunotherapy field for breast cancer (BC) treatment, especially in the triple‐negative subtype, the identification of reliable biomarkers capable of improving patient selection is paramount, because only a portion of patients seem to derive benefit from this appealing treatment strategy. In this context, the role of programmed cell death ligand 1 (PD‐L1) as a potential prognostic and/or predictive biomarker has been intensively explored, with controversial results. The aim of the present review is to collect available evidence on the biological relevance and clinical utility of PD‐L1 expression in BC, with particular emphasis on technical aspects, prognostic implications, and predictive value of this promising biomarker. Implications for Practice In the light of the promising results coming from trials of immune checkpoint inhibitors for breast cancer treatment, the potential predictive and/or prognostic role of programmed cell death ligand 1 (PD‐L1) in breast cancer has gained increasing interest. This review provides clinicians with an overview of the available clinical evidence regarding PD‐L1 as a biomarker in breast cancer, focusing on both data with a possible direct impact on clinic and methodological pitfalls that need to be addressed in order to optimize PD‐L1 implementation as a clinically useful tool for breast cancer management.

show abstract

Section: Resultsmentioning

confidence: 99%